Causal pathways of the effects of age and the CCR5-Δ32, CCR2-64I, and SDF-1 3′A alleles on AIDS development

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 3, 2005, Pages 321-326

  Geskus, Ronald B ^a,b   Meyer, Laurence ^c   Hubert, Jean Baptiste ^c   Schuitemaker, Hanneke ^d   Berkhout, Ben ^e   Rouzioux, Christine ^f   Theodorou, Ioannis D ^g   Delfraissy, Jean François ^c   Prins, Maria ^a   Coutinho, Roel A ^a  

^a MUNICIPAL HEALTH SERVICE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BICÊTRE HOSPITAL   (France)

^d CENTRAL LABORATORY   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Causal pathways; Cd4; Natural history; Risk factors; Viral load

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 64I; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 DELTA32; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGING; ALLELE; ARTICLE; COHORT ANALYSIS; DISEASE PREDISPOSITION; FOLLOW UP; GENE DELETION; GENE MUTATION; HOMOSEXUALITY; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; SEROCONVERSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGE FACTORS; ALLELES; CD4 LYMPHOCYTE COUNT; CHEMOKINES, CXC; COHORT STUDIES; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RNA, VIRAL;

EID: 21544476975     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000142017.25897.06     Document Type: Article

References (19)

1. De Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med. 1997;127:882-890.
2. van Rij RP, Broersen S, Goudsmit J, et al. The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS. 1998a;12:F85-F90.
3. van Rij RP, De Roda Husman AM, Brouwer M, et al. Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. J Infect Dis. 1998b;178:1806-1811.
4. Meyer L, Magierowska M, Hubert JB, et al., for the SEROCO Cohort, and van Rij R, Prins M, de Roda Husman AM, et al., for the Amsterdam Cohort Studies on AIDS. CC-chemokine receptor variants, SDF-1 polymorphism, and disease progression in 720 HIV-infected patients. AIDS. 1999;13:624-626.
5. Ioannidis JPA, Rosenberg PS, Goedert JJ, et al., for the International Meta-Analysis of HIV Host Genetics. Effects of CCR5-A32, CCR2-641, and SDF-1 3′A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med. 2001;135:782-795.
6. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science. 1998;279:389-393.
7. Meyer L, Magierowska M, Hubert JB, et al. Early protective effect of CCR-5 Δ32 heterozygosity on HIV-1 disease progression: relationship with viral load. AIDS. 1997;11:F73-F78.
8. Taylor JMG, Wang Y, Ahdieh L, et al. Causal pathways for CCR5 genotype and HIV progression. J Acquir Immune Defic Syndr Hum Retrovirol. 2000;23:160-171.
9. 8a. Geskus RB, Miedema FA, Goudsmit J, et al. Prediction of residual time to AIDS and death based on markers and cofactors. J Acquir Immune Defic Syndr Hum Retrovirol. 2003;32:514-521.
10. Ancelle-Park RA. European AIDS definition. Lancet. 1992;339:671.
11. Geskus RB. On the inclusion of prevalent cases in HIV/AIDS natural history studies through a marker-based estimate of time since seroconversion. Stat Med. 2000;19:1753-1769.
12. Hubert JB, Burgard M, Dussaix E, et al. Natural history of serum HIV-1 RNA levels in 330 patients with a known date of seroconversion. AIDS. 2000;14:123-131.
13. Agence française de securité sanitaire des produits de Santé. Annales du contrôle national de qualité. No. 17. 1999; Saint-Denis Cedex, France.
14. Hughes JP. Mixed effects models with censored data with application to HIV RNA levels. Biometrics. 1999;55:625-629.
15. Faucett CL, Thomas DC. Simultaneously modelling censored survival data and repeatedly measured covariates: a Gibbs sampling approach. Stat Med. 1996;15:1663-1685.
16. Spiegelhalter DJ, Thomas A, Best NG. WinBUGS version 1.2 User Manual. MRC Biostatistics Unit; 1999.
17. Gilks WR, Richardson S, Spiegelhalter DJ. Markov Chain Monte Carlo in Practice. London, England: Chapman & Hall; 1996.
18. Taylor JMG, Law N. Does the covariance structure matter in longitudinal modelling for the prediction of future CD4 counts? Stat Med. 1998;17: 2381-2394.
19. Mulherin SA, O'Brien TR, Ioannidis JPA, et al. Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS. 2003;17:377-387.